A1CNow+ Multi-Test HbA1c System consists of (1) a semi-disposable plastic-encased device (the monitor), (2) a plastic cartridge enclosing dry reagent strips, and (3) a sample dilution kit for: collecting the blood sample, mixing the sample with the required pre-treatment solution, and delivering the sample to the cartridge.
Publicado el 30 de octubre de 2024 · Inicio del retiro: 18 de septiembre de 2024
Resumen
FDA registra el retiro Z-0223-2025 de dispositivos médicos de Clase II, publicado el 30 de octubre de 2024 e iniciado el 18 de septiembre de 2024. Empresa responsable: Polymer Technology Systems, Inc. dba PTS Diagnostics, Inc.; Estado: Completado; Cantidad reportada: 2,452 units; Lote: UDI-DI: 00381933021011 Lot Numbers: 9331803, 2323019. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Completed — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
The reason for this recall is PTS Diagnostics, Inc. received complaints of non-matching cartridge and analyzer codes within the product test system box. Use of cartridges and analyzers with non-matching codes may result in inaccurate test results as components within each lot number are meant to be used together, and not mixed between lots. Therefore, the test results may possibly lead to Hemoglobin A1C positive or negative bias results. While the product is for monitoring only, over recovery with a higher than accurate value can be an indication for increased therapy; such as physical activity, weight reduction, meal management, pharmaceutical therapy.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Polymer Technology Systems, Inc. dba PTS Diagnostics, Inc.
- Distribuidor
- Worldwide distribution - US Nationwide and the countries of Japan, South Africa.
- Lote
- UDI-DI: 00381933021011 Lot Numbers: 9331803, 2323019
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAAD-TECH Spencer Probe Depth Electrode, REF SD08R-AP58X-000 8-Contact 1.12mm (A style) Depth Electrode30 de octubre de 2024
- FDAQuantum Perfusion Systems for CPB, Roller Pumps use peristaltic action to propel blood through the venous and30 de octubre de 2024
- FDAAD-TECH Spencer Probe Depth Electrode, REF SD06R-AP58X-000 6-Contact 1.12mm (A style) Depth Electrode30 de octubre de 2024
- FDAEZDilate Wire Guided Balloon- Indicated for use in adult and adolescent (> 12 years) populations to30 de octubre de 2024
- FDAAD-TECH Spencer Probe Depth Electrode, REF SD04R-AP58X-000 4-Contact 1.12mm (A style) Depth Electrode30 de octubre de 2024
- FDABoston Scientific myLUX Patient Application for an Apple Mobile device, Model Number 2939, Version 2.0.101,30 de octubre de 2024
Preguntas sobre este retiro
¿A1CNow+ Multi-Test HbA1c System consists of (1) a semi-disposable plastic-encased device (the monitor), (2) a plastic cartridge enclosing dry reagent strips, and (3) a sample dilution kit for: collecting the blood sample, mixing the sample with the required pre-treatment solution, and delivering the sample to the cartridge. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0223-2025 el 30 de octubre de 2024. Peligro reportado: The reason for this recall is PTS Diagnostics, Inc. received complaints of non-matching cartridge and analyzer codes within the product test system box. Use of cartridges and analyzers with non-matching codes may result in inaccurate test results as components within each lot number are meant to be used together, and not mixed between lots. Therefore, the test results may possibly lead to Hemoglobin A1C positive or negative bias results. While the product is for monitoring only, over recovery with a higher than accurate value can be an indication for increased therapy; such as physical activity, weight reduction, meal management, pharmaceutical therapy.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter